In prostate cancer cells, androgens can inhibit UGT2B17 expression by activating the androgen receptor, and glucuronidation leads to increased androgen secretion in the body, which will promote prostate cancer progression, forming a vicious cycle (37). Here, UGT2B17 is linked to prostate cancer.